Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Pacira Pharm Inc (PCRX)

Pacira Pharm Inc (PCRX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,294,616
  • Shares Outstanding, K 42,033
  • Annual Sales, $ 421,030 K
  • Annual Income, $ -11,020 K
  • 60-Month Beta 1.20
  • Price/Sales 3.25
  • Price/Cash Flow 18.87
  • Price/Book 3.83

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/20
See More
  • Average Estimate 0.14
  • Number of Estimates 5
  • High Estimate 0.27
  • Low Estimate -0.08
  • Prior Year 0.04
  • Growth Rate Est. (year over year) +250.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
27.46 +14.42%
on 03/23/20
38.97 -19.37%
on 03/10/20
-8.70 (-21.68%)
since 03/06/20
3-Month
27.46 +14.42%
on 03/23/20
51.35 -38.82%
on 02/19/20
-12.45 (-28.38%)
since 01/06/20
52-Week
27.46 +14.42%
on 03/23/20
51.35 -38.82%
on 02/19/20
-8.31 (-20.92%)
since 04/05/19

Most Recent Stories

More News
29.4% Return Seen to Date on SmarTrend Pacira Pharmaceu Call (PCRX)

SmarTrend identified a Downtrend for Pacira Pharmaceu (NASDAQ:PCRX) on February 26th, 2020 at $45.63. In approximately 1 month, Pacira Pharmaceu has returned 29.39% as of today's recent price of $32.22....

PCRX : 31.45 (+2.11%)
Pacira (PCRX) Down 37.2% Since Last Earnings Report: Can It Rebound?

Pacira (PCRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

PCRX : 31.45 (+2.11%)
Look for Shares of Pacira Pharmaceu to Potentially Pullback after Yesterday's 3.87% Rise

Pacira Pharmaceu (NASDAQ:PCRX) traded in a range yesterday that spanned from a low of $30.57 to a high of $33.62. Yesterday, the shares gained 3.9%, which took the trading range above the 3-day high...

PCRX : 31.45 (+2.11%)
Why You Shouldn't Bet Against Pacira BioSciences (PCRX) Stock

Pacira BioSciences (PCRX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

PCRX : 31.45 (+2.11%)
Pacira (PCRX) is an Incredible Growth Stock: 3 Reasons Why

Pacira (PCRX) possesses solid growth attributes, which could help it handily outperform the market.

PCRX : 31.45 (+2.11%)
The Zacks Analyst Blog Highlights: UnitedHealth, Pacira, Turning Point, Coca-Cola and Sempra

The Zacks Analyst Blog Highlights: UnitedHealth, Pacira, Turning Point, Coca-Cola and Sempra

UNH : 244.64 (+6.60%)
SRE : 115.16 (+10.43%)
KO : 46.31 (+5.66%)
PCRX : 31.45 (+2.11%)
TPB : 20.79 (-0.29%)
PCRX or ZTS: Which Is the Better Value Stock Right Now?

PCRX vs. ZTS: Which Stock Is the Better Value Option?

PCRX : 31.45 (+2.11%)
ZTS : 126.00 (+9.94%)
5 Best Stocks to Buy in a Coronavirus-Led Bear Market

The period of a typical bear market has a propensity to be pretty lengthy. On average, bear market for the Dow and the S&P 500 lasts 206 and 146 trading days, respectively.

UNH : 244.64 (+6.60%)
SRE : 115.16 (+10.43%)
KO : 46.31 (+5.66%)
PCRX : 31.45 (+2.11%)
TPB : 20.79 (-0.29%)
Shares of PCRX Down 20.0% Since Downtrend Call on Shares

SmarTrend identified a Downtrend for Pacira Pharmaceu (NASDAQ:PCRX) on February 26th, 2020 at $45.63. In approximately 2 weeks, Pacira Pharmaceu has returned 19.96% as of today's recent price of $36.52....

PCRX : 31.45 (+2.11%)
Why Pacira (PCRX) Could Be an Impressive Growth Stock

If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider Pacira (PCRX)

PCRX : 31.45 (+2.11%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strongest short term outlook on maintaining the current direction.

See More Share

Trade PCRX with:

Business Summary

Pacira Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development, commercialization and manufacture of new pharmaceutical products, based on its proprietary DepoFoam drug delivery technology, for use in hospitals and ambulatory surgery centers. Pacira Pharmaceuticals, Inc....

See More

Key Turning Points

2nd Resistance Point 33.75
1st Resistance Point 32.27
Last Price 31.45
1st Support Level 29.91
2nd Support Level 29.03

See More

52-Week High 51.35
Fibonacci 61.8% 42.23
Fibonacci 50% 39.41
Fibonacci 38.2% 36.59
Last Price 31.45
52-Week Low 27.46

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar